Abstract

A method comprising is described herein comprising receiving first magnetic resonance imaging (MRI) data of a first plurality of subjects, wherein the first MRI image data comprises a first plurality of two-dimensional (2D) images, pre-processing the first MRI data for analysis, converting each two-dimensional image of the first plurality of 2D images into first tokens as input for a transformer encoder, wherein the transformer encoder comprises a time series classification transformer, training the transformer encoder using the first input tokens, receiving second MRI data of a subject, wherein the second MRI data comprises a second plurality of 2D images, converting each image of the second plurality of 2D images into second tokens as input to the trained transformer encoder, and applying the trained transformer encoder to the second tokens to predict a state of disease in a subject.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G06T 7/11 - Region-based segmentation

Abstract

Hydrophilic nanoparticles are disclosed comprising CuS and a hydrophobic surface. Also disclosed are amphiphilic polymeric nanoparticles useful in transporting the CuS or other hydrophobic payloads, and composites containing the polymeric nanoparticles and the hydrophobic CuS payloads. This system can be used, for example, to modulate plant growth and development, resulting in improved yields, crop quality, and shelf life.

IPC Classes  ?

• C01G 3/12 - Sulfides
• A61K 9/51 - Nanocapsules
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• B82Y 40/00 - Manufacture or treatment of nanostructures
• C08L 97/00 - Compositions of lignin-containing materials

Abstract

A subconjunctival implant and a method for treating an eye infection in an eye of a subject by placing the subconjunctival implant into a subconjunctival space of the eye. The subconjunctival implant includes an elongated body portion and a fin. At least one of the elongated body portion or the fin comprises a biocompatible polymer and a medication. The elongated body portion includes a leading edge and a trailing edge opposite the leading edge. The elongated body portion includes a dorsal surface and an anterior surface. The fin extends from the dorsal surface. The fin has a sloped leading surface extending from the dorsal surface to an apex of the fin and a trailing surface transverse to the dorsal surface and extending from the apex to the dorsal surface.

IPC Classes  ?

• A61F 2/14 - Eye parts, e.g. lenses or corneal implantsArtificial eyes

Abstract

Therapeutics and methods of treating a stroke in a patient comprising delivering stem cells into a peritoneum of the patent. According to a further embodiment the stem cells are mesenchymal stem cells. According to a further embodiment the stem cells are human placenta mesenchymal stem cells (hPMSC). According to a further embodiment the stroke is one of stroke is one of occlusive, post-occlusive, hemorrhagic, and transient ischemic injury. According to a further embodiment the method further comprises the step of delivering a clot busting compound into a blood stream of the patient.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The avirulent strain A257 of the bacterial rice pathogen Burkholderia glumae is an effective priming material to reduce or suppress major diseases in rice and other plants. Protection includes that against bacterial panicle blight, sheath blight, and narrow brown leaf spot. A mutant derivative of A257, A257ΔqsmR, significantly reduces the risk that the priming agent might potentially revert to wild-type pathogenicity.

IPC Classes  ?

• A01H 1/00 - Processes for modifying genotypes
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/01 - Bacteria or actinomycetales

Abstract

A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as Pneumocystis spp. The vaccine may be used to prevent or to treat fungal infections. The novel vaccine can provide protective immunity, even for immunocompromised individuals such as HIV patients having reduced levels of CD4+ T cells.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 38/19 - CytokinesLymphokinesInterferons
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 9/58 - Proteinases derived from fungi
• C12N 9/60 - Proteinases derived from fungi from yeast

Abstract

A genetically modified non-human animal comprising a genome containing an endogenous non-human ACE2 locus genetically modified to encode a complete human ACE2 gene. According to a further embodiment the genome is genetically modified to encode a second, a third, and a fourth complete human ACE2 gene, the human ACE2 gene is at least 85 percent identical to SEQ ID No: 1, the animal of is a mouse, the human ACE2 gene encodes six protein variants, an endogenous Tmprss2 gene is unmodified, a LoxP gene flanks each of a 5′ and a 3′ end of a nucleic acid sequence of the human ACE2 gene, and the human ACE2 gene is expressed in a lung, kidney, spleen, stomach, liver, intestine, heart, and skeletal muscle of the animal, and a cortex, striatum, middle brain, hippocampus, olfactory bulb, and cerebellum of a brain of the animal.

IPC Classes  ?

• A01K 67/0278 - Knock-in vertebrates, e.g. humanised vertebrates
• A01K 67/0276 - Knock-out vertebrates
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Systems, methods, and computer-readable storage media for simulating a non-homogenous space environment. A system can include a ion beam generator, a moderator block, a radiation detector, at least one processor which can execute operations including: transmitting, 7o the ion beam generator, a beam generation signal, the beam generation signal specifying an energy level of an ion beam and a duration of the ion beam, the ion beam making first contact with the moderator block and subsequent contact with a test animal; receiving, from the radiation detector after the duration of the ion beam is completed, energy deposition within the test animal. The system can then execute computational models to determine moderator block computational results animal computational results, then generate projected human results for the ion beam based on the moderator block computational results and the animal computational results.

IPC Classes  ?

• G01T 1/29 - Measurement performed on radiation beams, e.g. position or section of the beamMeasurement of spatial distribution of radiation
• G21G 4/04 - Radioactive sources other than neutron sources

Abstract

A method and apparatus for evaluating soybean quality are disclosed. Automated or semi-automated image processing can be implemented with commercially available machine vision hardware. Post-harvest soybeans are separated, imaged, and analyzed to assess grain quality factors used in official grading. The system may be used prior to sale, purchase, further harvesting, or planting subsequent crops. The system reduces inspection errors, reduces variance in results, increases efficiency, enhances repeatability, and improves the standardization of soybean quality evaluation. Shape analysis, color analysis, and Haralick texture analysis are employed to determine when certain types of damage are present, to distinguish between types of damage, and to classify grains as smooth, cracked, or wrinkled. The system is sufficiently robust to allow successful deployment in rural, remote, and non-standard environments.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 7/11 - Region-based segmentation
• G06T 7/40 - Analysis of texture
• G06T 7/50 - Depth or shape recovery
• G06T 7/90 - Determination of colour characteristics

Abstract

The herbicide-tolerant, high-amylose rice cultivar LA21-2150 and its hybrids and derivatives are disclosed.

IPC Classes  ?

• A01G 22/22 - Rice
• A01H 5/10 - Seeds
• A01N 43/647 - TriazolesHydrogenated triazoles
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

This invention is directed to methods of preventing, treating, or alleviating a symptom of a venous thromboembolic event in a subject.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/37 - Coumarins, e.g. psoralen
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/727 - HeparinHeparan
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors

Abstract

In one aspect, the disclosure relates to In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to acetylated glycosides comprising at least one O, S, or Se atom external to the glycoside ring, wherein the O, S, or Se is bonded to a moiety selected from C1-C20 linear or branched alkyl, alkenyl, aryl, alkylaryl, or arylalkyl. Also disclosed are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating or preventing viral diseases and their symptoms in a subject using the same. In one aspect, the glycosides target host cell glycan decoration of viral proteins and do not cause the viruses to mutate. In another aspect, the glycosides and pharmaceutical compositions comprising the same can be applied topically and thereby do not cause systemic side effects in the subject.

IPC Classes  ?

• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61K 31/7008 - Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
• C07H 5/06 - Aminosugars
• C07H 5/08 - Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium, or tellurium
• C07H 5/10 - Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium, or tellurium to sulfur
• C07H 13/04 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
• C07H 13/08 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
• C07H 15/02 - Acyclic radicals, not substituted by cyclic structures
• A61P 31/14 - Antivirals for RNA viruses

Abstract

This disclosure provides compounds, pharmaceutical compositions, and methods of use for the prevention and treatment of inflammatory diseases or degenerative diseases including neurodegenerative diseases. Embodiments of the present disclosure provide compounds related to very long chain polyunsaturated fatty acids, pharmaceutical compositions containing the provided compounds, and methods of treating a subject with a condition or disease using provided compounds or pharmaceutical compositions.

IPC Classes  ?

• C07C 57/03 - Monocarboxylic acids
• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 31/232 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07C 59/42 - Unsaturated compounds containing hydroxy or O-metal groups
• C07C 69/587 - Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
• C07C 69/732 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
• C07F 9/10 - Phosphatides, e.g. lecithin

Abstract

The disclosed invention relates to methods and transgenic non-human mammals comprising a full length human VIPR2 genomic region integrated into a genome of the mammal. According to a further embodiment the mammal is a mouse. The disclosed invention further relates to transgenic cells from the transgenic non-human mammal. The disclosed invention further relates to therapeutics and methods of treating Schizophrenia in a human comprising administering a therapeutic, where the therapeutic contains one of a pharmacologically effective amount of a hVIPR2 antagonist, and a CRISPR/Cas9 formulation. The disclosed invention further relates to materials and methods of determining efficacy of an antipsychotic therapeutic in treating a condition comprising administering to the transgenic non-human mammal.

IPC Classes  ?

• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• A01K 67/0278 - Knock-in vertebrates, e.g. humanised vertebrates

Abstract

This invention is directed to compositions and methods to detect and treat gastrointestinal diseases.

IPC Classes  ?

• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes

Abstract

This invention is directed to neuroprotective compositions and methods of using the same to treat neurodegenerative diseases.

IPC Classes  ?

• A61K 31/426 - 1,3-Thiazoles
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 277/40 - Unsubstituted amino or imino radicals
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

The present disclosure provide systems and methods for well control. One such method comprises positioning a fiber optic sensor along a length of a wellbore or a wellbore structure positioned within the wellbore: obtaining fiber optic sensing data acquired by the fiber optic sensor and an optical interrogator: processing the fiber optic sensing data to identify a multiphase fluid flow or a gas signature of gas within the wellbore: tracking a movement of the gas along the length of the optical cable by determining a flow velocity of the moving gas or a lower density phase of the moving gas with respect to a surrounding fluid: detecting a presence of the moving gas towards a surface of the wellbore or a surface of the wellbore structure; and/or transmitting a control signal to a controller of machinery operating in the wellbore after detecting the presence of the moving gas.

IPC Classes  ?

• G01H 9/00 - Measuring mechanical vibrations or ultrasonic, sonic or infrasonic waves by using radiation-sensitive means, e.g. optical means
• E21B 47/113 - Locating fluid leaks, intrusions or movements using electrical indicationsLocating fluid leaks, intrusions or movements using light radiation
• G01K 11/32 - Measuring temperature based on physical or chemical changes not covered by group , , , or using changes in transmittance, scattering or luminescence in optical fibres
• G01L 11/02 - Measuring steady or quasi-steady pressure of a fluid or a fluent solid material by means not provided for in group or by optical means
• G01V 1/22 - Transmitting seismic signals to recording or processing apparatus

Abstract

A device is described herein comprising lateral bodies configured for contact with a vertebral endplate of a subject, wherein the lateral bodies comprise a first lateral body and a second lateral body, wherein the first lateral body and the second lateral body are connected using linking elements, wherein the linking elements comprise a first linking element and a second linking element; wherein the linking elements are configured for adjustable spacing of the lateral bodies relative to each other.

IPC Classes  ?

• A61F 2/44 - Joints for the spine, e.g. vertebrae, spinal discs
• A61F 2/30 - Joints

Abstract

A method for slot-drill enhanced oil recovery in a formation includes providing a wellbore in a reservoir of the formation, the reservoir having a top and a bottom, cutting a first horizontal slot-drill fracture at the top of the reservoir, cutting a second horizontal slot-drill fracture at the bottom of the reservoir, injecting a fluid into the reservoir via the first horizontal slot-drill fracture at the top of the reservoir, and producing oil from the second horizontal slot-drill fracture at the bottom of the reservoir. The first horizontal slot-drill fracture is parallel to the second horizontal slot-drill fracture.

IPC Classes  ?

• E21B 43/30 - Specific pattern of wells, e.g. optimising the spacing of wells
• E21B 43/26 - Methods for stimulating production by forming crevices or fractures

Abstract

The invention provides a method of preventing, treating, and/or preventing the recurrence of cancer in a subject by administering to the subject a therapeutically effective amount of a GPR84 antagonist. Further, the invention provides a method of modulating the immune system of a subject afflicted with or at risk of cancer. Still further, the invention provides a method of preventing or treating an inflammatory response in a subject. Also provided is a method of preventing an immune system disease or disorder in a subject. Further, the invention provides a method treating an immune system disease or disorder in a subject. Also, the invention provides a method of modulating the immune system of a subject afflicted with or at risk of an immune system disease or disorder.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/282 - Platinum compounds
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

In one aspect, the disclosure relates to a system and method for detecting leaks in fluid handling systems, including, but not limited to, wells, pipelines, and storage tanks for natural gas and petroleum products. In another aspect, the system includes one or more optical fiber sensors having fiber Bragg gratings (FBGs) wherein a perturbation of the system causes a reflected wavelength shift. In the disclosed method, data collected from the FBG-containing sensors is detrended using a non-linear detrending algorithm after subtracting a synthetic baseline from raw data, thereby extracting and quantifying leak-based signatures. The disclosed system can detect micro-leaks and generates substantially no false positives.

IPC Classes  ?

• G01M 3/04 - Investigating fluid tightness of structures by using fluid or vacuum by detecting the presence of fluid at the leakage point
• G01M 3/28 - Investigating fluid tightness of structures by using fluid or vacuum by measuring rate of loss or gain of fluid, e.g. by pressure-responsive devices, by flow detectors for pipes, cables, or tubesInvestigating fluid tightness of structures by using fluid or vacuum by measuring rate of loss or gain of fluid, e.g. by pressure-responsive devices, by flow detectors for pipe joints or sealsInvestigating fluid tightness of structures by using fluid or vacuum by measuring rate of loss or gain of fluid, e.g. by pressure-responsive devices, by flow detectors for valves

Abstract

The invention relates to a method of producing a tendon neotissue from a population of adipose-derived stem cells (ASCs) subjected to mechanical and biological stimulations in a bioreactor system. The tendon neotissues are effective as implants to treat tendon or ligament injury in a subject. The invention also relates to a customized bioreactor useful for producing a tri-dimensional engineered tissue.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor

Abstract

This invention is directed to recombinant ACE2 polypeptides and fragments thereof, compositions comprising the same, and methods for using the same to treat disease.

IPC Classes  ?

• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• C07K 14/81 - Protease inhibitors
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Disclosed herein are methods for diagnosing and therefore treating infectious bovine keratoconjunctivitis (IBK) or squamous cell carcinoma (OSCC) in cattle. The methods involve a novel panel of qPCR primer targets, including Bovine GAPDH, Moraxella bovis, Moraxella bovoculi, Mycoplasma, Staphylococcus, Pasteurellaceae, Prevotellaceae, and Weeksellaceae that can be normalized with primers for Universal Bacteria and Escherichia coli. Also provided are coefficients for each of these targets for use in analyzing sample data and predicting IBK or OSCC in cattle.

IPC Classes  ?

• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

The present disclosure provides for concrete joint and crack sealants, methods of using sealants, and kits including the components to form sealants, and the like. In an aspect, the present disclosure provides for concrete joint and crack sealant, where the sealant includes or consists essentially of: a porous expandable skeleton comprising pores; and a filler comprising a two-way shape memory polymer (2W-SMP), wherein the filler fills the pores.

IPC Classes  ?

• B29C 65/54 - Applying the adhesive between pre-assembled parts
• B29C 65/70 - Joining of preformed partsApparatus therefor by moulding
• C08F 236/06 - Butadiene
• C08K 5/00 - Use of organic ingredients
• E04B 1/68 - Sealings of joints, e.g. expansion joints
• E04C 5/07 - Reinforcing elements of material other than metal, e.g. of glass, of plastics, or not exclusively made of metal
• E04C 5/16 - Auxiliary parts for reinforcements, e.g. connectors, spacers, stirrups

Abstract

Methods of evaluating mechanical damage are disclosed relating to fatigue life progression that include the evaluation of temperature differentials against stress dependent damage parameters for mechanical objects. Evaluation of the remaining useful life of such mechanical objects may be conducted by comparing a stabilized stressed temperature to a reference temperature for the mechanical object. The methods may be used to determine remaining useful life without benefit of a prior fatigue history.

IPC Classes  ?

• G01N 3/18 - Performing tests at high or low temperatures
• G01N 3/08 - Investigating strength properties of solid materials by application of mechanical stress by applying steady tensile or compressive forces
• G01N 3/12 - Pressure-testing
• G01N 3/32 - Investigating strength properties of solid materials by application of mechanical stress by applying repeated or pulsating forces
• G01N 3/56 - Investigating resistance to wear or abrasion

Abstract

The invention features indolealkylamine compounds and pharmaceutical compositions useful for treating 5-HT2 responsive conditions. Also provided are methods of using the compounds or compositions of the invention for treating 5-HT2 responsive conditions such as depression or inflammation in a subject in need thereof.

IPC Classes  ?

• C07D 209/16 - Tryptamines
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07C 217/60 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring

Abstract

This invention is directed to vaccine compositions and methods of using the same to prevent infection.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 14/40 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from fungi from yeasts from Candida

Abstract

A replicating in vitro cell culture of human placental mesenchymal stem cells comprising; cells which maintain a potential to differentiate to derivatives of multiple progenitor cell types throughout the culture. The progenitor cell types may include neuronal cells, oligodendrocytes and beta-cells. A method of treating a disease, disorder, or condition in a human comprising administering a pharmacologically effective dose of human placental mesenchymal stem cells to the human. A method for producing human placental mesenchymal stem cells.

IPC Classes  ?

• A61K 35/50 - PlacentaPlacental stem cellsAmniotic fluidAmnionAmniotic stem cells
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
• C12N 5/079 - Neural cells
• C12N 5/0793 - Neurons

Abstract

In one aspect, the disclosure relates to compounds comprising one or more lignin derivatives, at least one organic peroxide, and a pharmaceutically-acceptable carrier. In an aspect, the one or more lignin derivatives can be or include thiolated lignosulfonate (TLS), sodium lignosulfonate (SLS), or a combination thereof. In one aspect, the SLS can be grafted to a polymer or copolymer such as poly(lactic-co-glycolic) acid (PLGA) in order to form a shell of a core-shell nanoparticle, wherein the shell surrounds a core of the inorganic peroxide and protects the core from premature activation in an aqueous wound environment. In another aspect, the pharmaceutically-acceptable carrier can be a hydrogel forming polymer such as a methacrylated gelatin, which can assist in modulating the properties of the lignin derivatives to be suitable for injection. Also disclosed herein are methods of using the disclosed compositions for the treatment of wounds in subjects, including in diabetic subjects.

IPC Classes  ?

• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 33/08 - OxidesHydroxides
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

The disclosure is drawn towards compositions and methods for treating and preventing senescence, mitochondrial dysfunction, and related diseases and disorders.

IPC Classes  ?

• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 11/06 - Antiasthmatics

Abstract

The present invention relates to compositions and methods of use thereof.

IPC Classes  ?

• A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
• A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/33 - Heterocyclic compounds

Abstract

The present disclosure provides for compositions, methods of making the composition, and devices (e.g., vascular grafts, self-expandable stents, balloon-expandable stents, and stent-grafts) having the composition disposed thereof. The composition can include a polymer nanoparticle (e.g., charged or uncharged) made of polymers that have one or more types of agents covalently bonded to the polymer. In this regard, the one or more types of agents are not physically encapsulated by the polymer, rather are covalently bonded to the polymer that makes up the polymeric nanoparticle. In another aspect, an agent can also be encapsulated in the polymer of the polymeric nanoparticle. In another embodiment, the composition includes two types of polymeric nanoparticles, where a first polymeric nanoparticle has at least one agent covalently bonded to the polymer of the first polymeric nanoparticle and where the composition can also include a second polymeric nanoparticle encapsulating an agent.

IPC Classes  ?

• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 29/06 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 29/16 - Biologically active materials, e.g. therapeutic substances
• A61L 31/06 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances

Abstract

Disclosed are various approaches for using controlled fractures in geothermal systems. In some examples, a method includes drilling at least one injection well bore. The method can also include cutting at least a first slot at an angle to the injection well bore, where the first slot has a first end connected to the injection well bore and a distal end. The method can include cutting at least a second slot at an angle to the injection well bore, where the second slot has a first end connected to the distal end of the first slot and a distal end. The method can also include drilling at least one production well bore, where the production well bore is connected to the distal end of the second slot.

IPC Classes  ?

• F24T 10/20 - Geothermal collectors using underground water as working fluidGeothermal collectors using working fluid injected directly into the ground, e.g. using injection wells and recovery wells
• E21B 7/00 - Special methods or apparatus for drilling
• E21B 11/06 - Other drilling tools with driven cutting chains or similarly-driven tools
• F24T 10/00 - Geothermal collectors

Abstract

A computing system may include at least one processor and a memory. The computing system may be configured to: present a processing speed and working memory task to a user; receive first input from the user regarding the processing speed and working memory task; present a verbal task to the user; receive second input from the user regarding the verbal task; based on the first input and the second input, determine a cognitive performance score for the user; and provide a recommendation regarding care for the user based on the cognitive performance score.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A63F 13/80 - Special adaptations for executing a specific game genre or game mode
• A63F 9/18 - Question-and-answer games
• G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
• G16H 10/00 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data
• G09B 5/00 - Electrically-operated educational appliances
• G09B 7/00 - Electrically-operated teaching apparatus or devices working with questions and answers

Abstract

This invention pertains to anti-CSE phosphospecific antibodies, phosphomimetic mutant polypeptides and fragments, and uses thereof to diagnose and treat tissue injury.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

Therapeutics and methods treating Alzheimer's disease or a pre-Alzheimer's disease condition in a patient comprising administering a pharmaceutical composition containing a therapeutically effective dose therapeutic, wherein the therapeutic contains a PRMT4 inhibitor, or a pharmaceutically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof. According to a further embodiment, the PRMT4 inhibitor is one of TP-064 and SCFFBXO9.

IPC Classes  ?

• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 38/45 - Transferases (2)
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Serratia Serratia anticancer polysaccharide (PS1), methods of making the same, pharmaceutical compositions comprising the same, and methods of treating tumors using same. In one aspect, the disclosed compounds contain a repeating polysaccharide unit and a lipid linked to the polysaccharide either by an ester bond or a phosphodiester bond. In another aspect, the disclosed compounds and methods are effective against a variety of tumor types through the mechanism of tumor capillary hemorrhage and do not cause systemic side effects such as, for example, antibody-mediated immune responses in subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

IPC Classes  ?

• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
• A61K 39/02 - Bacterial antigens
• A61P 31/04 - Antibacterial agents
• A61P 35/00 - Antineoplastic agents
• C12N 1/20 - BacteriaCulture media therefor
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds

Abstract

Aspects of the invention are drawn to a Raman spectroscopy system that incorporates a tissue probe into a thin sheath that is adapted to fit any flexible or rigid laryngoscope. The Raman probe system can comprise a probe, a laser source, an excitation signal filter, a collection filter, a charge couple device detector, a signal collection system, a housing unit, a computer, a display, or a combination thereof. In certain embodiments, the signal collection system comprises a spectrum collection range of about 200 cm-1 to about 4000 cm.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 1/01 - Guiding arrangements therefor
• A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
• G01N 21/65 - Raman scattering

Abstract

Ion-pairs known as GUMBOS (group of uniform materials based on organic salts) from antiseptics (chlorhexidine and octenidine) and the beta-lactam antibiotic, ceftriaxone. The antimicrobial efficacy of these GUMBOS and unreacted stoichiometric equivalent mixtures were compared to ceftriaxone and azithromycin alone. On a molar basis, GUMBOS were equivalent to ceftriaxone and 10× more effective in killing N. gonorrhoeae than azithromycin. They were more than 100× more effective than either antibiotic in killing CRE. A strategy involving the electrostatic interaction between a common antiseptic and a discontinued antibiotic (octenidine and carbenicillin) was also evaluated as a treatment for gonorrhoea. Octenidine/carbenicillin is a novel group of uniform materials based on organic salts (GUMBOS) with inherent in vitro antibacterial activity that comes from its parent antiseptic and antibacterial ions, octenidine and carbenicillin, respectively.

IPC Classes  ?

• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• A61P 31/04 - Antibacterial agents

Abstract

A method for generating volumetric modulated arc therapy-computed tomography (VMAT-CT) including receiving, at a computer system comprising at least one processor, electronic portal imaging device (EPID) images collected during VMAT; performing Online Region-based Active Contour Method (ORACM) on the EPID images, resulting in binarized images; performing multi-leaf collimator (MLC) motion modeling on the binarized images, resulting in motion modeled EPID images with most of blurred regions within the EPID images removed; performing an outlier-filtering algorithm on the motion modeled EPID images, resulting in further filtered EPID images; executing a conventional FDK-based VMAT-CT reconstruction algorithm on the further filtered EPID images to provide FDK-reconstructed images; executing an iterative VMAT-CT reconstruction algorithm that combines compressed sensing and block matching and 3D filtering, on the FDK-reconstructed images, resulting in VMAT-CT images; and outputting the VMAT-CT images.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• G06T 11/00 - 2D [Two Dimensional] image generation

Abstract

A method of treating prostate cancer in a patient comprising administering to the patient a pharmaceutical composition including a first therapeutic including a TLK1B inhibitor, or a pharmaceutically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof, and a second therapeutic including an antiandrogen or a pharmaceutically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof.

IPC Classes  ?

• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61P 35/00 - Antineoplastic agents

Abstract

Male-sterile EGMS rice lines, both conventional and herbicide-tolerant, and their Fi hybrids are disclosed. The EGMS lines can produce Fi hybrids with high yield, desirable agronomic traits, and good milling characteristics.

IPC Classes  ?

• A01H 5/10 - Seeds
• A01H 6/46 - Gramineae or Poaceae, e.g. ryegrass, rice, wheat or maize

Abstract

This invention is directed to compositions and methods for detecting proteinopathies.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• H04L 67/1001 - Protocols in which an application is distributed across nodes in the network for accessing one among a plurality of replicated servers
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

A method of method of preventing or reversing diuretic resistance, the method comprising administering to the subject an amount of a kappa opioid receptor agonist (KOA) sufficient to selectively increase urine output, wherein the KOA decreases or does not change urinary excretion of electrolytes.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 31/4965 - Non-condensed pyrazines
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 38/07 - Tetrapeptides
• A61P 9/12 - Antihypertensives
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

A DC circuit breaker system includes a first mechanical switch, a first parallel capacitor connecting a first terminal and a second terminal of the first mechanical switch, a second mechanical switch in series with the first mechanical switch, a second parallel capacitor connecting a first terminal and a second terminal of the second mechanical switch, a first diode connecting the first terminal and the second terminal; and a second diode connecting the first terminal and the second terminal. The first mechanical switch separates contacts in response to a fault current; the second mechanical switch separates contacts in response to the fault current; and opening the first and second mechanical switches and turning off the first and second diodes reverses current flow and clears a current fault. The DC circuit breaker system may also be equipped with a surge arrestor at its input and a freewheeling diode at its output.

IPC Classes  ?

• H01H 33/59 - Circuit arrangements not adapted to a particular application of the switch and not otherwise provided for, e.g. for ensuring operation of the switch at a predetermined point in the AC cycle
• H01H 9/54 - Circuit arrangements not adapted to a particular application of the switching device and for which no provision exists elsewhere
• H01H 33/14 - Multiple main contacts for the purpose of dividing the current through, or potential drop along, the arc
• H02H 3/087 - Emergency protective circuit arrangements for automatic disconnection directly responsive to an undesired change from normal electric working condition, with or without subsequent reconnection responsive to excess current for DC applications

Abstract

A microRNA sensing platform is disclosed that is sensitive, accurate, easy to use, affordable, and that does not require expensive equipment on the part of the end-user. The sensing system can be used as a sensitive and accurate miRNA profiling platform to monitor the progression of diseases, or treatment regimen, or personalized diagnosis, or personalized prognosis. The entire RNA-induced silencing complex (RISC), which holds the mature miRNA, is preserved in the system. The RISC is allowed to perform its native functions. These native functions not only protect the miRNA from degradation during the isolation process, but can also help eliminate false targets. The system sensitively and selectively responds to the presence or absence of RISCs bearing the target miRNA.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

Aspects of the invention are drawn to a pelvic internal fixation system and methods of using the same to fix one hemipelvis to the other.

IPC Classes  ?

• A61B 17/86 - Pins or screws

Abstract

Compositions and methods are described herein for transdifferentiation of multipotent stromal cells into cells that can express insulin.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells

Abstract

An embodiment of a DC circuit breaker system includes a first mechanical switch, a first parallel capacitor connecting a first terminal and a second terminal of the first mechanical switch, a second mechanical switch in series with the first mechanical switch, a second parallel capacitor connecting a first terminal and a second terminal of the second mechanical switch, a first diode connecting the first terminal and the second terminal; and a second diode connecting the first terminal and the second terminal. According to the present disclosure, the first mechanical switch initiates a separation of contacts in response to a fault current; the second mechanical switch initiates a separation of contacts in response to the fault current; and opening of the first and second mechanical switches and turning off of the first and second diodes reverse a direction of a current flow and clear a current fault.

IPC Classes  ?

• H02H 7/26 - Sectionalised protection of cable or line systems, e.g. for disconnecting a section on which a short-circuit, earth fault, or arc discharge has occurred

Abstract

Oral formulations comprising one or more proteasome inhibitors for use as a treatment of coronavirus infection in a subject. Also disclosed are the use of such for the treatment or prevention of SARS-CoV-2 infection in humans.

IPC Classes  ?

• A61K 31/69 - Boron compounds
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/07 - Tetrapeptides
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Aspects of the invention are drawn to methods for treating or preventing a bacterial infection in a subject. Further aspects of the invention are drawn to methods for sensitizing an antibiotic resistant bacterial infection to an antibiotic.

IPC Classes  ?

• A61P 31/04 - Antibacterial agents
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• A61K 38/20 - Interleukins
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61Q 17/00 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings

Abstract

The herbicide-tolerant rice cultivar designated 'CLL19' and its hybrids and derivatives are disclosed.

IPC Classes  ?

• A01H 6/46 - Gramineae or Poaceae, e.g. ryegrass, rice, wheat or maize
• A01G 22/22 - Rice
• A01H 1/04 - Processes of selection
• A01H 5/10 - Seeds
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

A surgical alignment device is described herein comprising an alignment head, wherein the alignment head comprises a plurality of tool access holes, a k-wire hole array comprising a first plurality of k-wire holes and a second plurality of k-wire holes, wherein the first plurality of k- wire holes extends radially from a first surface of the alignment head to a second surface of the alignment head, wherein the second plurality of k-wire holes are parallel to the plurality of tool access holes.

IPC Classes  ?

• A61B 17/17 - Guides for drills
• A61B 17/15 - Guides therefor
• A61B 17/84 - Fasteners therefor
• A61B 17/88 - Methods or means for implanting or extracting internal fixation devices
• A61F 2/46 - Special tools for implanting artificial joints

Abstract

The invention relates to a Quadruple Gene Deleted Mutant Bovine Herpesvirus Type 1 (BHV-1 QMV) engineered to express protective antigens derived from viruses associated with infection in livestock. The recombinant vector includes a deletion of a cytoplasmic tail of envelope glycoprotein gE (gE-CT), a truncation of glycoprotein gG, a deletion of envelope protein UL49.5 amino acid residues 30-32, and a deletion of UL49.5 cytoplasmic tail amino acid residues 80-96. The truncation of glycoprotein gG comprises a deletion of amino-terminal amino acid residues 1-67. The recombinant vector can include at least two heterologous antigens inserted therein. Included are methods for creating recombinant vectors, mutant viruses, and vaccines for preventing or reducing symptoms associated with viral infection in livestock, in particular bovine respiratory viral infection

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

Therapeutics and methods of diagnosing non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in a patient comprising obtaining a sample from the patient, determining a level of a signaling lymphocytic activation molecule 1 (SLAMF1) in the sample from the patient, and diagnosing the patient with NAFLD when the level of the SLAMF1 is at least an elevated threshold level for the SLAMF1. Therapeutics and methods of treating non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in a patient in need of treatment comprising administering a pharmaceutically effective dose of a therapeutic, wherein the therapeutic includes a signaling lymphocytic activation molecule 1 (SLAMF1) antagonist.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

This disclosure relates to methods of use related to omega-3 very-long-chain polyunsaturated fatty acids (n-3 VLC-PUFA) and their hydroxylated derivatives known as elovanoids to alleviate a symptom of, treat, or prevent disease. Furthermore, this invention is directed to compositions and methods for modulating VLC-PUFA bioactivity and availability.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61P 39/00 - General protective or antinoxious agents

Abstract

The absorbance or emission wavelength of composite materials comprising a transition metal doped shell disposed over a rare earth doped core and a functionalizable group on the surface of the transition metal doped shell can change upon subjection to a carboxylic acid. This method of changing the absorbance or emission wavelength of a composite material can be used to identify counterfeit currency using an ink comprising a composite material.

IPC Classes  ?

• C09K 11/77 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing rare earth metals
• B41M 3/14 - Security printing
• B42D 25/29 - Securities Bank notes
• B42D 25/305 - Associated digital information
• B42D 25/378 - Special inks
• C09D 11/00 - Inks
• C09K 11/02 - Use of particular materials as binders, particle coatings or suspension media therefor

Abstract

In Provided are embodiments of a recombinant nucleic acid comprising a nucleotide sequence encoding a live-attenuated kin chimeric Herpes Simplex Vims Type-1 (HSV-1) VC2 virus and a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter, wherein the heterologous polypeptide can replace the glycoprotein C (gC) openreading frame (ORF) in VC2, and wherein the nucleotide sequence encoding the heterologous polypeptide can encode the influenza virus hemagglutinin A or a fragment thereof. The constructs may be incorporated in a vaccine effective in generating antibodies against influenza hemagglutinin.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• C07K 14/11 - Orthomyxoviridae, e.g. influenza virus
• C12N 15/86 - Viral vectors
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

Disclosed herein are compositions and methods for treating glioblastoma.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/15 - Oximes (C=N—O—)Hydrazines (N—N)Hydrazones (N—N=)
• A61K 31/33 - Heterocyclic compounds

Abstract

A method of treating or preventing methamphetamine related endothelial dysfunction in a patient comprising administering to the patient an effective dose of a pharmacologic composition; the composition comprising a therapeutic, the therapeutic including a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. The H2S donor may be one of sodium sulfide, diallyl trisulfide, diallyl disulfide, acillin, sugammadex, sulfanilamide, disulfram, sulfonamide, sulfinates, sulfoxides, persulfides, polysulfides, and sulfones. The H2S donor may be sugammadex. The H2S donor may be administered in a dosage of between 0.5 mg/kg and 10.0 mg/kg.

IPC Classes  ?

• A61K 31/724 - Cyclodextrins
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C12N 9/88 - Lyases (4.)

Abstract

The present invention is directed to method of producing a bovine blastoid and uses thereof.

IPC Classes  ?

• C08G 63/181 - Acids containing aromatic rings
• C08G 63/02 - Polyesters derived from hydroxy carboxylic acids or from polycarboxylic acids and polyhydroxy compounds

Abstract

This disclosure is directed is directed to compositions and methods for preventing, treating, or ameliorating the symptoms of a viral infection.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention is directed to bovine trophoblast stem cells and uses thereof.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention provides rolled scaffold devices and cell culture systems that can provide a large surface-area-to-volume ratio for expanded cell culture. The rolled scaffolds minimize shear stress on cultured cells and support sufficient and uniform mass transfer rates of gases and nutrients. The rolled scaffolds can be connected to a media source via holders to support large-scale expansion and maintenance of cell cultures.

IPC Classes  ?

• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• B32B 27/28 - Layered products essentially comprising synthetic resin comprising copolymers of synthetic resins not wholly covered by any one of the following subgroups
• B32B 27/26 - Layered products essentially comprising synthetic resin characterised by the use of special additives using curing agents

Abstract

The present invention is directed to a protein aggregation assay, and methods of use thereof.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/483 - Physical analysis of biological material
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

A composition and method are disclosed for forming lignin-containing floccules from dissolved lignin, lignin nanoparticles, lignin colloids, or lignin-containing cellulose nanofibers. The floccules may be used to clean oil-contaminated materials such as oil-contaminated plastics or oil-contaminated water. The polymers and oil may then be recovered for further use, without requiring organic solvents.

IPC Classes  ?

• C02F 1/56 - Macromolecular compounds
• B01J 20/24 - Naturally occurring macromolecular compounds, e.g. humic acids or their derivatives
• C02F 1/52 - Treatment of water, waste water, or sewage by flocculation or precipitation of suspended impurities
• C02F 1/68 - Treatment of water, waste water, or sewage by addition of specified substances, e.g. trace elements, for ameliorating potable water
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• C02F 101/32 - Hydrocarbons, e.g. oil
• C02F 103/00 - Nature of the water, waste water, sewage or sludge to be treated
• C02F 103/08 - Seawater, e.g. for desalination
• E02B 15/04 - Devices for cleaning or keeping clear the surface of open water from oil or like floating materials by separating or removing these materials

Abstract

Embodiments of the present disclosure provide for embodiments of a panel of oligonucleotides for use in a multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) assay for the identification of rotavirus A and B and genotypes thereof. Another aspect of the disclosure encompasses embodiments of an RT-PCR multiplex method for determining whether an equine is infected with an equine rotavirus.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

Aspects of the invention are drawn to compositions and methods of treating a 5-HT2-mediated condition in a subject in need thereof. In embodiments, the 5-HT2-mediated condition is a 5-HT2A-mediated ocular condition. In some embodiments, the ocular condition is associated with decreased lacrimation or tear film production (e.g., dry eye), in certain embodiments, the ocular condition is associated with increased IOP (e.g., glaucoma).

IPC Classes  ?

• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 9/10 - DispersionsEmulsions
• A61P 27/02 - Ophthalmic agents

Abstract

Disclosed herein are furan fatty acid synthetic compounds and furan fatty acid – amino acid conjugates.

IPC Classes  ?

• C07C 53/128 - Acids containing more than four carbon atoms the carboxyl group being bound to a carbon atom bound to at least two other carbon atoms, e.g. neo-acids
• C07C 233/47 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
• C07C 233/49 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
• C07D 307/54 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

A respiratory tidal volume monitor and feedback device (RTVMFD) comprising a frame, a flow channel tube attached to the frame, a mass flow sensor disposed on the flow channel tube to detect air flow through the flow channel tube, a microcontroller unit attached to the frame and electrically connected to the mass flow sensor via a bus, the microcontroller unit having a system processor, a system memory, and a system clock, a visual display attached to a top of the frame, the visual display being electrically connected to the bus. According to a further embodiment, the RTVMFD further comprises an audio output attached to the frame and electrically connected to the bus.

IPC Classes  ?

• A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
• A61M 16/08 - BellowsConnecting tubes
• A61M 16/06 - Respiratory or anaesthetic masks
• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine

Abstract

System and methods for enabling a mobile robot for autonomous missions are described. Despite some mobile robots having the capability of safely traversing complex terrains, mobile robots still behave like a typical machine which can only respond to a human's commands via an interactive controller. For example, a human will drive the mobile robot to desired locations, position it, and activate actions as desired in order to complete a mission. As such, it is desirable to enable a mobile robot with the capability of executing and completing a mission without a human's involvement. The present disclosures includes innovative technology which enables an ordinary user to quickly define a complex mission in the form that a mobile robot can understand and automatically execute it accordingly.

IPC Classes  ?

• G05D 1/02 - Control of position or course in two dimensions
• G01C 21/00 - NavigationNavigational instruments not provided for in groups

Abstract

A tyrosine kinase inhibitor for use in the treatment of COVID-19 and/or its associated symptoms. Also disclosed is a method of treating an individual infected with a coronavirus, wherein said method comprises the steps of: providing a tyrosine kinase inhibitor; and administering said tyrosine kinase inhibitor to said individual in a dosage amount sufficient to prevent/stabilize/reduce the risks and/or symptoms associated with a coronavirus infection.

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Aspects of this invention is directed to compositions and methods for treating the visual cycle as well as the survival and function of cones and rods in patients with retinal degeneration.

IPC Classes  ?

• A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention is directed to a modular anatomical system for demonstrating, practicing, or evaluating a medical procedure or technique.

IPC Classes  ?

• G09B 23/34 - Anatomical models with removable parts
• G09B 23/00 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes
• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
• G09B 23/30 - Anatomical models
• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations

Abstract

Provided are thiol-acrylate hydrogels and tunable cell culture materials including thiol-acrylate hydrogels, and methods of making thereof. Also provided are systems for forming three-dimensional cell culture scaffolds including the materials, and methods of culturing cells, including cancer cells, using thiol-acrylate hydrogels and tunable cell culture materials. The materials herein can be used in microfluidic droplet-generating devices.

IPC Classes  ?

• C12N 5/09 - Tumour cells
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C08G 75/04 - Polythioethers from mercapto compounds or metallic derivatives thereof

Abstract

A method and system for identification of light source types includes detecting individual photons for a measurement time period to provide a times series of individual photon events, segmenting the time series into a plurality of time bins, and determining a number of detected photons within each time bin to provide a time series of photon counts, determining a probability distribution P(n) from the time series of photon counts, the probability distribution providing the probability of detection of n photons (n=0 . . . nmax), inputting each of the values of P(n) as a nmax+1 component feature vector into a single neuron neural network that has been previously trained on a plurality of light source types, and receiving as output a classifier that has a value that identifies the light source type. An average number of photons in the plurality of time bins is less than one photon.

IPC Classes  ?

• G01J 1/02 - Photometry, e.g. photographic exposure meter Details
• G01J 1/44 - Electric circuits
• G06N 3/04 - Architecture, e.g. interconnection topology

Abstract

Systems, methods, and non-transitory computer-readable storage media for identifying potential therapeutics for pathogens (bacterial or viral). The system can receive a plurality of molecules known to have interactions with a pathogen, fragment the plurality of molecules into a plurality of linkers and a plurality of rigids, and remove redundancies from the plurality of linkers and the plurality of rigids. The system can then identify a plurality of possible molecules formed from the fragments, evaluate those possible molecules for toxicity, and analyze the non-toxic candidates using a convolutional neural network associated with the pathogen. The final candidates can then be used for in-vivo testing.

IPC Classes  ?

• G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
• G16B 40/30 - Unsupervised data analysis

Abstract

Systems, methods, and non-transitory computer-readable storage media for an adjustable neural network. Systems measure feature applicability for an octave of a Convolutional Neural Network (CNN) at a standard scale, resulting in (1) at least one drop-off point where the octave no longer resonates with pre-defined features; and (2) a common drop-off between the CNN and at least one other CNN trained on at least one other separate domain. The system can then measure octave resonance for a plurality of CNNs trained on large data sets with a distribution of octaves for features, and measure a pattern of octaves learned in the CNN, resulting in a measurement pattern. The system can then compare that measurement pattern to the pre-defined features, resulting in a level of adaptability of the CNN, and modify the CNN based on the level of adaptability of the CNN, resulting in a modified CNN.

IPC Classes  ?

• G06N 3/045 - Combinations of networks
• G06N 3/096 - Transfer learning

Abstract

A system and method are provided for reconstructing 3-D point cloud. A light source generates light that is received by a polarization field generator, which generates a polarization field that illuminates the target object being imaged such that each outgoing ray has a unique polarization state. A camera captures images of the illuminated target object and the captured images are received by a processor that: (1) performs a polarization field decoding algorithm that decodes the polarization field to obtain a set of incident rays; (2) performs a camera ray decoding algorithm to obtain a set of camera rays; (3) performs a ray-ray intersection algorithm that determines intersection points where the incident rays and the camera rays intersect; and (4) performs a 3-D reconstruction algorithm that uses the set of incident rays, the set of camera rays and the intersection points to reconstruct a 3-D point cloud of the target object.

IPC Classes  ?

• G02F 1/1335 - Structural association of cells with optical devices, e.g. polarisers or reflectors
• G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour
• H04N 13/207 - Image signal generators using stereoscopic image cameras using a single 2D image sensor
• H04N 13/254 - Image signal generators using stereoscopic image cameras in combination with electromagnetic radiation sources for illuminating objects

Abstract

The present invention is directed to a surgical evacuation device and associated methods of use. The presently disclosed surgical evacuator is configured for use during aerosol-generating procedures to protect health care workers from exposure to potentially infectious aerosolized particles.

IPC Classes  ?

• A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems

Abstract

Provided are devices and methods for injecting viable transplant tissues into a subject. The device includes a fluid exchange chamber having a funneled portion connected to a pre-injection tube. The chamber includes fluid transfer holes and is disposed in an outer shell having a central bore connecting a top inlet and a bottom outlet from which the pre-injection tube exits the shell. A plunger having a central channel and a tapered bottom is disposed in the central bore such that the tapered bottom mates the funneled bottom when depressed and a stylet plunger is disposed in the central channel of the plunger.

IPC Classes  ?

• A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing

Abstract

This invention is directed to combination compositions and methods for treating cancer, including brain cancer and its metastasis.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61P 35/00 - Antineoplastic agents
• A61K 31/232 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol

Abstract

A composition and method for killing feral hogs: a bait that is attractive to hogs is mixed with a lethal amount of sodium nitrite, along with sufficient base to inhibit decomposition of the sodium nitrite. At sufficiently high pH, encapsulation of the sodium nitrite is not required to inhibit decomposition. In the absence of substantial decomposition, the sodium nitrite itself is not aversive to the pigs, and may even enhance acceptance of the baits by the pigs. Optionally, an anti-emetic compound is added to the mixture to reduce the likelihood the bait will be vomited. Optionally, an additional toxicant such as luteolin is added to the mixture.

IPC Classes  ?

• A01N 59/00 - Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds

Abstract

Embodiments of the present application are directed toward a focusing Schlieren technique that is capable of adding color-coded directional information to the visualization of density gradients. Other advantages of the technique can include that it does not require manual calibration, has a simple design and is sensitive enough to be used in compact experimental setups. Certain embodiments include the use of a color-coded source image that replaces the conventional source grid. The technique may benefit from a computer-controlled digital background, which is used for both illumination and display of color-coded source images.

IPC Classes  ?

• G01N 21/45 - RefractivityPhase-affecting properties, e.g. optical path length using interferometric methodsRefractivityPhase-affecting properties, e.g. optical path length using Schlieren methods
• H04N 17/02 - Diagnosis, testing or measuring for television systems or their details for colour television signals

Abstract

Provided for are methods of producing triacylglycerol-accumulated microalgae, methods for making bioplastics from triacylglycerol-accumulated microalgae, methods for making alga-mixed plastics, and products including these bioplastics. Methods of triacylglycerol accumulation using centrifugation are also provided. Products such as plastic beads and other consumer products can be made from the bioplastics described herein.

IPC Classes  ?

• C12N 1/12 - Unicellular algaeCulture media therefor
• A01G 33/00 - Cultivation of seaweed
• C08H 99/00 - Subject matter not provided for in other groups of this subclass
• C08L 99/00 - Compositions of natural macromolecular compounds or of derivatives thereof not provided for in groups or
• C12P 7/6463 - Glycerides obtained from glyceride producing microorganisms, e.g. single cell oil

Abstract

The present disclosure provides for systems and methods for selectively oxidizing methane to methanol, devices including reactors, reactors for selectively oxidizing methane to methanol, method of making coated reactor tubes of reactors, and the like. In an aspect, the system can have the characteristic of a per pass methanol yield of greater than 8% and selectivities of greater than 70% for methane to methanol.

IPC Classes  ?

• C07C 29/48 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by oxidation reactions with formation of hydroxy groups
• C07C 31/04 - Methanol
• C07C 31/02 - Monohydroxylic acyclic alcohols
• C01B 3/02 - Production of hydrogen or of gaseous mixtures containing hydrogen

Abstract

The herbicide-tolerant rice cultivar designated ‘PVL03’ and its hybrids and derivatives are disclosed.

IPC Classes  ?

• A01H 6/46 - Gramineae or Poaceae, e.g. ryegrass, rice, wheat or maize
• A01H 5/10 - Seeds
• A01H 1/00 - Processes for modifying genotypes

Abstract

The invention is directed to compositions and methods for treating metabolic disorders.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 9/08 - Solutions
• A61K 9/10 - DispersionsEmulsions
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present disclosure provides for devices and methods that actively circulate air into a helmet and around a wearer's face and head. Advantageously, the devices described herein can be added to off-the-shelf protective helmets and can leverage existing passive ventilation features to actively circulate fresh air without compromising protection against mechanical forces. The devices can be added to helmets on a temporary, permanent, or semi-permanent basis and can be used alongside additional protective accessories such visors, lenses, and/or face guards. The devices and methods described herein are be suitable to virtually all protective helmets (e.g. athletic or safety helmets). The devices described herein are portable, non-restrictive, and fully contained in the interior of the helmet. Helmets with integral forced-air circulation are also provided.

IPC Classes  ?

• A42B 3/28 - Ventilating arrangements
• A42B 3/06 - Impact-absorbing shells, e.g. of crash helmets

Abstract

This invention is directed to methods of treating disease characterized by aberrations in the ubiquitin proteasome system (UPS).

IPC Classes  ?

• A61K 36/282 - Artemisia, e.g. wormwood or sagebrush
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61P 35/00 - Antineoplastic agents

Abstract

Provided herein, inter alia, are compositions and methods for treating or preventing viral infections. The methods and compositions may modulate entry of a virus into a cell, viral fusion to a cell, or cell to cell spread of the virus by targeting one or more viral proteins or ligands thereof. The methods and compositions provided herein including embodiments thereof are contemplated to be especially effective for treating or preventing cytomegalovirus infections.

IPC Classes  ?

• A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present disclosure presents nanostructure-based localized surface plasmon resonance systems and related methods. In this regard, a method comprises applying a body fluid sample to a metal surface of the nanostructure-based LSPR biosensor with linker, intermediate, and capture/probe antibodies; illuminating the metal surface of the nanostructure-based LSPR biosensor with the monochromatic, broadband, or laser light; measuring an intensity or spectrum of absorbed, reflected, transmitted, or scattered exiting light from the nanostructure-based LSPR biosensor having the body fluid sample and comparing the measured intensity or spectrum with a reference intensity; detecting a spectral shift of exiting light from the nanostructure-based LSPR biosensor having the body fluid sample; and signaling that the body fluid sample is positive for a presence of a particular biomaterial in response to detecting the spectral shift of the exiting light, wherein the biomaterial has binded or adsorbed to the metal surface of the nanostructure-based LSPR biosensor.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator

Abstract

This invention is directed to towards methods of identifying a subject with insulin resistance. For example, this invention is drawn to adjusting C-peptide urinary excretion rate for average glucose concentration to identify a subject with insulin resistance.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value

Abstract

This invention is directed to compositions, methods and kits for ameliorating or reducing pathogenesis of a disease by administering to a subject a serotonin receptor agonist.

IPC Classes  ?

• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61P 27/02 - Ophthalmic agents
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/48 - Ergoline derivatives, e.g. lysergic acid, ergotamine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Methods for treatment for patients suffering from disease or condition are contemplated as including an administration of an intravenous infusion of a pharmaceutically effective amount of psilocybin or psilocin. The intravenous infusion of psilocybin or psilocin may include an additional compound such as a benzodiazepine, preferably lorazepam, administered via a continuous intra-venous infusion. Such methods may be seen to better alleviate the symptoms of psychological conditions, neurological injuries, pain, or inflammatory condition, and may result in reduced need for other medications.

IPC Classes  ?

• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61P 25/24 - Antidepressants
• A61P 25/22 - Anxiolytics
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Modulation of inward potassium ion conductance with structurally diverse small-molecules in the arthropod salivary gland induces arthropod salivary gland failure that results in a reduction or elimination in the ability of the arthropod to feed. Administering Kir channel inhibitors reduces food intake, increases feeding time, reduces salivary gland secretion, induces mortality, and reduces transmission of vector-borne pathogens. Kir channel inhibitors induce these adverse effects in ticks, mosquitoes, horn flies, and aphids.

IPC Classes  ?

• A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
• A01N 43/38 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings condensed with carbocyclic rings
• A01N 43/56 - 1,2-DiazolesHydrogenated 1,2-diazoles
• A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system

Abstract

Protected quantum dots are protected from degradation, particularly in aqueous environments, The system comprises quantum dots, hydrophobic core, and hydrophilic shell. The quantum dots are entrapped in and protected by the hydrophobic core. The core polymer is covalently bonded to a hydrophilic shell polymer or protein. Quantum yield is better maintained than for non-encapsulated quantum dots in an aqueous environment. Optionally, ligands are attached to the hydrophilic shell to target delivery of the protected quantum dots, In an alternative embodiment, quantum dots are entrapped in the hydrophilic shell, or in both the shell and the core.

IPC Classes  ?

• C09K 11/02 - Use of particular materials as binders, particle coatings or suspension media therefor
• C09K 11/88 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing selenium, tellurium or unspecified chalcogen elements
• A61K 49/00 - Preparations for testing in vivo

Abstract

The present disclosure provides a DC mechanical circuit breaker that can utilize two switches, one of which can generate zero-crossing with an alternate oscillatory circuit for the other one, which can be a conventional zero-crossing-based AC breaker and can be used in the main circuit. This is different from the conventional single-switch commute-and-absorb method currently used. The present disclosure shows that disclosed circuit breaker improves the fault current extinction and significantly reduces the voltage rate-of-change while creating the current zero-crossing faster compared to the available technology. Thus, disclosed circuit breaker is capable of interrupting high DC currents with minimal arc through a less expensive AC circuit breaker. Simulation and hardware results are provided to show the efficiency of the disclosed circuit breaker.

IPC Classes  ?

• H02H 3/087 - Emergency protective circuit arrangements for automatic disconnection directly responsive to an undesired change from normal electric working condition, with or without subsequent reconnection responsive to excess current for DC applications
• G01R 31/327 - Testing of circuit interrupters, switches or circuit-breakers
• H01H 9/54 - Circuit arrangements not adapted to a particular application of the switching device and for which no provision exists elsewhere
• H01H 33/59 - Circuit arrangements not adapted to a particular application of the switch and not otherwise provided for, e.g. for ensuring operation of the switch at a predetermined point in the AC cycle
• H02H 1/06 - Arrangements for supplying operative power
• H02H 3/02 - Emergency protective circuit arrangements for automatic disconnection directly responsive to an undesired change from normal electric working condition, with or without subsequent reconnection Details
• H02H 9/02 - Emergency protective circuit arrangements for limiting excess current or voltage without disconnection responsive to excess current
• H03K 17/13 - Modifications for switching at zero crossing

Abstract

The present invention relates to a resin composition comprising 20-70 wt % of an aromatic di(meth)acrylate component; 5-25 wt % of a flexible di(meth)acrylate component; and 10-70 wt % of a crosslinker component; wherein the resin composition further comprises: 0.1-10 phr initiator; 0-10 phr silica; and 5-50 phr milled carbon fiber. The invention also relates to a polymerized coating disposed over a substrate, the coating comprising 20-70 wt % aromatic di(meth)acrylate subunits; 5-25 wt % flexible di(meth)acrylate subunits; and 10-70 wt % crosslinker subunits; wherein the coating further comprises: 0.1-10 phr silica; and 5-50 phr milled carbon fiber. The invention also relates to a method of depositing a coating over a substrate, the method comprising the steps of: providing a resin composition; applying the resin composition over a substrate; and polymerizing the resin composition to form a solid coating.

IPC Classes  ?

• C09D 133/10 - Homopolymers or copolymers of methacrylic acid esters
• C08K 3/36 - Silica
• C08K 3/04 - Carbon
• C08K 5/14 - Peroxides
• C08L 33/10 - Homopolymers or copolymers of methacrylic acid esters
• C09D 7/61 - Additives non-macromolecular inorganic
• B05D 7/14 - Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials to metal, e.g. car bodies
• C09D 7/63 - Additives non-macromolecular organic
• B05D 3/02 - Pretreatment of surfaces to which liquids or other fluent materials are to be appliedAfter-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by baking
• B05D 3/10 - Pretreatment of surfaces to which liquids or other fluent materials are to be appliedAfter-treatment of applied coatings, e.g. intermediate treating of an applied coating preparatory to subsequent applications of liquids or other fluent materials by other chemical means